TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05931692

Intervention type: DIAGNOSTIC_TEST
Intervention: Virtual reality
Description: Virtual environment that triggers fear of falling

Intervention type: DIAGNOSTIC_TEST
Intervention: Virtual reality
Description: Virtual environment that triggers fear of falling

Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalogram
Description: Detect brain waves in response to fear of falling

Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalogram
Description: Detect brain waves in response to fear of falling

Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: Measures muscle activity and response to fear of falling

Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: Measures muscle activity and response to fear of falling

Intervention type: DIAGNOSTIC_TEST
Intervention: Motion Capture system
Description: Measures postural and gait responses to fear of falling

Intervention type: DIAGNOSTIC_TEST
Intervention: Motion Capture system
Description: Measures postural and gait responses to fear of falling

Intervention type: DIAGNOSTIC_TEST
Intervention: Polar H10 Heart Sensor
Description: Heart rate monitor

Intervention type: DIAGNOSTIC_TEST
Intervention: Polar H10 Heart Sensor
Description: Heart rate monitor

Intervention type: DIAGNOSTIC_TEST
Intervention: Inertial measurement Unite
Description: Measure Postural sway

Intervention type: DIAGNOSTIC_TEST
Intervention: Inertial measurement Unite
Description: Measure Postural sway
Study: NCT05667220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin monotherapy group (Group A): 20 eligible patients were planned to be included and given Sitagliptin 100 mg Qd orally; the treatment period was 1 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin combined with Beidougen capsule
Description: Sitagliptin combined with Beidougen capsule treatment group (Group B): 20 eligible patients were planned to be included and given sitagliptin 100mg Qd orally combined with Beidougen capsule 60mg Tid orally. The treatment period was 1 week.
Study: NCT06034587

Intervention type: DIAGNOSTIC_TEST
Intervention: multimodal ultrasound
Description: An Aixplorer ultrasound machine (SuperSonic Imaging, Ltd, Aixen-Provence, France), equipped with AngioPLUS(AP) and shear wave elastography(SWE) functions, was used for all examinations using a 4-15MHz linear probe.AP function can detect microvessels of lesions,SWE can evaluate the stiffness of lesions and high frequency ultrasound can measure the thickness and volume of keloid.

Intervention type: DIAGNOSTIC_TEST
Intervention: multimodal ultrasound
Description: An Aixplorer ultrasound machine (SuperSonic Imaging, Ltd, Aixen-Provence, France), equipped with AngioPLUS(AP) and shear wave elastography(SWE) functions, was used for all examinations using a 4-15MHz linear probe.AP function can detect microvessels of lesions,SWE can evaluate the stiffness of lesions and high frequency ultrasound can measure the thickness and volume of keloid.

Intervention type: RADIATION
Intervention: radioisotope applicator therapy
Description: The radioisotope applicator therapy utilized 90Sr-90Y(0094SR814975) isotope, customized by the China Atomic Energy Research Institute. The element therapy instrument used had overall dimensions of 2.8cm x 2.8cm, with an effective treatment area of 2.0cm x 2.0cm. It delivered a radiation dose of 5.0Gy/h. Each patient received superficial radiation therapy through a single 90Sr source, administered in repeated doses. The isotope therapy instrument was customized to fit the exact size of the keloid, ensuring coverage the irradiation range extending 0.5cm beyond the keloid's edge. During treatment, the surface of the applicator was aligned with the irradiated area and directly contact the surface of the keloid tissue. The treatment was carried out low-dose irradiation method, over 5 sessions, with each session delivering a dose of 2Gy. Each irradiation lasted for 25min.

Intervention type: RADIATION
Intervention: radioisotope applicator therapy
Description: The radioisotope applicator therapy utilized 90Sr-90Y(0094SR814975) isotope, customized by the China Atomic Energy Research Institute. The element therapy instrument used had overall dimensions of 2.8cm x 2.8cm, with an effective treatment area of 2.0cm x 2.0cm. It delivered a radiation dose of 5.0Gy/h. Each patient received superficial radiation therapy through a single 90Sr source, administered in repeated doses. The isotope therapy instrument was customized to fit the exact size of the keloid, ensuring coverage the irradiation range extending 0.5cm beyond the keloid's edge. During treatment, the surface of the applicator was aligned with the irradiated area and directly contact the surface of the keloid tissue. The treatment was carried out low-dose irradiation method, over 5 sessions, with each session delivering a dose of 2Gy. Each irradiation lasted for 25min.
Study: NCT06106386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: Cooling of irrigation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: Cooling of irrigation
Study: NCT05738057

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D-TACE
Description: TACE with Cisplatin-Eluting Beads (with Cis 30mg). More TACE can be done if clinically necessary.
Study: NCT05090579

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group I (BN10)
Description: patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine, 1 mL of 10 mg of nalbuphine plus 4 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator:Group ll (BN20)
Description: patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine, 2 mL of 20 mg of nalbuphine plus 3 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator:Group lll (B)
Description: patients will receive 20 mL of 0.25%bupivacaine plus 5 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
Study: NCT06580691

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcision plus Plasma gel injection Vs Subcision plus Cog PDO threads
Description: Plasma Gel: was injected into the scarred areas immediately after subcision. Thread Treatment: Cog PDO threads were inserted using a blunt-tipped cannula in a Z pattern within the scarred areas, filling the pockets created by subcision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcision plus Plasma gel injection Vs Subcision plus Cog PDO threads
Description: Plasma Gel: was injected into the scarred areas immediately after subcision. Thread Treatment: Cog PDO threads were inserted using a blunt-tipped cannula in a Z pattern within the scarred areas, filling the pockets created by subcision.
Study: NCT06579222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Care Rheumatology Family Physician Consultation
Description: The participant will be booked with a primary care rheumatology family physician for rheumatoid arthritis comorbidity screening. They will complete weight, height, blood pressure measurement, assess for risk factors for dyslipidemia, type 2 diabetes, hypertension, bone mineral density loss and vaccine preventable infectious diseases.
Study: NCT04592770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nature based walk therapy
Description: 10 minutes stretching exercises followed by walk in nature for 50 minutes

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sit in nature
Description: Sit in nature for 60 minutes
Study: NCT06574009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal pain care
Description: Behavioral therapy (as below), physical therapy, assistive devices (e.g. TENS, bracing), referrals to VA specialists (e.g. interventional pain), and complementary and integrative therapies (e.g. acupuncture or massage

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal pain care
Description: Behavioral therapy (as below), physical therapy, assistive devices (e.g. TENS, bracing), referrals to VA specialists (e.g. interventional pain), and complementary and integrative therapies (e.g. acupuncture or massage

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal pain care
Description: Behavioral therapy (as below), physical therapy, assistive devices (e.g. TENS, bracing), referrals to VA specialists (e.g. interventional pain), and complementary and integrative therapies (e.g. acupuncture or massage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication optimization
Description: Medications will be optimized following an algorithm the investigators created based upon NCCN's Survivorship Guidelines and AHRQ's comprehensive review of non-opioid treatments for chronic pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication optimization
Description: Medications will be optimized following an algorithm the investigators created based upon NCCN's Survivorship Guidelines and AHRQ's comprehensive review of non-opioid treatments for chronic pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication optimization
Description: Medications will be optimized following an algorithm the investigators created based upon NCCN's Survivorship Guidelines and AHRQ's comprehensive review of non-opioid treatments for chronic pain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buprenorphine rotation
Description: Subjects randomized to this arm at 6 months will be offered the chance to rotate from their full mu agonist opioid to buprenorphine using a standardized protocol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buprenorphine rotation
Description: Subjects randomized to this arm at 6 months will be offered the chance to rotate from their full mu agonist opioid to buprenorphine using a standardized protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid tapering
Description: Subjects randomized to tapering will receive recommendations based upon the VA PBM's opioid tapering reference guide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid tapering
Description: Subjects randomized to tapering will receive recommendations based upon the VA PBM's opioid tapering reference guide
Study: NCT06418373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Get Ready with My Heart Program
Description: In the intervention group, adolescent CHD patients undergo a comprehensive assessment by cardiology and cardiothoracic experts to determine their suitability for transitional care management. Based on the Get Ready with My Heart Program, a personalized transition plan is developed, offering courses and resources that enhance self-management skills such as medication management, symptom monitoring, and health record maintenance. Throughout the transition period, regular support and follow-ups are provided to ensure that both patients and their families are adequately supported. The program includes regular assessments of transition readiness and quality of life changes to understand the intervention's impact and make necessary adjustments. Additionally, feedback is actively collected from patients and their families to continuously improve and refine the program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional intervention
Description: Adolescent CHD patients and their caregivers receive comprehensive health education and medical management. Upon admission, a detailed assessment of each patient's medical history and physical examination is conducted. A treatment and perioperative care plan is then tailored, including medication management with anticoagulants and antiarrhythmics, and surgery-related health guidance. Regular cardiac monitoring and follow-up assessments ensure treatment effectiveness and health status updates. Post-discharge, patients receive lifestyle management advice through remote consultations, focusing on diet and physical activity. Additionally, training on recognizing and managing emergencies is provided, equipping patients and caregivers to handle potential crises effectively. This holistic approach aims to improve both immediate and long-term health outcomes for adolescent CHD patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional intervention
Description: Adolescent CHD patients and their caregivers receive comprehensive health education and medical management. Upon admission, a detailed assessment of each patient's medical history and physical examination is conducted. A treatment and perioperative care plan is then tailored, including medication management with anticoagulants and antiarrhythmics, and surgery-related health guidance. Regular cardiac monitoring and follow-up assessments ensure treatment effectiveness and health status updates. Post-discharge, patients receive lifestyle management advice through remote consultations, focusing on diet and physical activity. Additionally, training on recognizing and managing emergencies is provided, equipping patients and caregivers to handle potential crises effectively. This holistic approach aims to improve both immediate and long-term health outcomes for adolescent CHD patients.
Study: NCT06196229

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Action Observation Therapy
Description: During each training session, participants were asked to observe a specific object-directed daily action presented on a computer screen, and afterward they performed what they have observed, 5 repetitions of each task, time duration was noted .~16 motor tasks related to their daily living that were performed with their own hands which are following~1. Folding a towel~2. Cutting a toilet roll~3. Using scissors~4. Tightening shoelaces~5. Opening and closing a square airtight container~6. Opening a bottle top~7. Turning a faucet~8. Using a field of billfold~9. Drinking water~10. Setting a seal~11. Changing batteries~12. Opening and closing a zipper~13. Turning over pages of a book~14. Plugging the outlet~15. Spraying water with a sprayer~16. Sorting chopsticks and spoons and putting them in a box • The participants were advised to keep focusing on their affected arm/hand action observational tasks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy combined with Virtual Reality
Description: In the VRT group, participants will execute VR-based activities conducted by the same therapist.~* 16 tasks will be assigned in each session. VR SHINECON 3D Glasses will be used~* The virtual environment was set in a 6 m2 physical space~* At the beginning of each session, the participant will sit in the center of the set zone and will be assisted to wear the VR glasses~* After the participant will confirm that the sight and sound is clear and comfortable, the tasks mentioned in action observation therapy will be done using virtual reality videos~* The Extrinsic feedback will be provided, including the time left, number of repetitions, and record number of repetitions
Study: NCT06295237

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intellisync+
Description: mechanical ventilator software automatically detecting and adjusting ventilator parameters to control or reduce the number of events.
Study: NCT04557865

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-PMPBB3 (APN-1607) PET imaging
Description: 1. Name: 18F-PMPBB3 (APN-1607, MNI-958, or APN-0000455)~2. Dosage form: injection form~3. Strength: 5mCi/dose~4. Dosage and administration: 5mCi, intravenous injection~5. Mechanism of action (if known): bind to tau protein in the brain~6. Pharmacological category: radiopharamceutical
Study: NCT06646185

Intervention type: OTHER
Group type: OTHER
Intervention: Menstrual Pads
Description: Participants adopt menstrual pads to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.
Study: NCT05054374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirdametinib
Description: Dose Level -2INT: 2mg PO BID, 3 weeks on/1 week off Dose Level -2: 2mg PO BID given continuously Dose Level -1INT: 3mg PO BID, 3 weeks on/1 week off Dose Level -1: 3mg PO BID given continuously Dose Level 1: 4mg PO BID given continuously Dose Level 2: 6mg PO BID given continuously Dose Level 3: 8mg PO BID given continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirdametinib
Description: Dose Level -2INT: 2mg PO BID, 3 weeks on/1 week off Dose Level -2: 2mg PO BID given continuously Dose Level -1INT: 3mg PO BID, 3 weeks on/1 week off Dose Level -1: 3mg PO BID given continuously Dose Level 1: 4mg PO BID given continuously Dose Level 2: 6mg PO BID given continuously Dose Level 3: 8mg PO BID given continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirdametinib
Description: Dose Level -2INT: 2mg PO BID, 3 weeks on/1 week off Dose Level -2: 2mg PO BID given continuously Dose Level -1INT: 3mg PO BID, 3 weeks on/1 week off Dose Level -1: 3mg PO BID given continuously Dose Level 1: 4mg PO BID given continuously Dose Level 2: 6mg PO BID given continuously Dose Level 3: 8mg PO BID given continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirdametinib
Description: Dose Level -2INT: 2mg PO BID, 3 weeks on/1 week off Dose Level -2: 2mg PO BID given continuously Dose Level -1INT: 3mg PO BID, 3 weeks on/1 week off Dose Level -1: 3mg PO BID given continuously Dose Level 1: 4mg PO BID given continuously Dose Level 2: 6mg PO BID given continuously Dose Level 3: 8mg PO BID given continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: The starting dose of mirdametinib in combination with fulvestrant in each Dose Level will be as follows:~* Dose Level 1: mirdametinib 4 mg BID PO + fulvestrant~* (Only to be triggered pending DLTs on higher Dose Levels as described below)~  * Dose Level -2: mirdametinib 2 mg BID PO continuous + fulvestrant, and Dose Level -2INT: mirdametinib 2 mg BID PO on 3 weeks on, 1 week off + fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: The starting dose of mirdametinib in combination with fulvestrant in each Dose Level will be as follows:~* Dose Level 1: mirdametinib 4 mg BID PO + fulvestrant~* (Only to be triggered pending DLTs on higher Dose Levels as described below)~  * Dose Level -2: mirdametinib 2 mg BID PO continuous + fulvestrant, and Dose Level -2INT: mirdametinib 2 mg BID PO on 3 weeks on, 1 week off + fulvestrant
Study: NCT06215950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70 CAR-T cells
Description: After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70 CAR-T cells
Description: After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally
Study: NCT05513274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Psychology Neuroscience + Written Emotional Disclosure
Description: A 15 to 20-minute exercise which they examine variables in themselves that suggest that their pain is driven by central nervous system processes. Participants will then write for 20 minutes about their very deepest thoughts and feelings about the most traumatic experience of their lives. A 10-minute break followed by writing again for 20 minutes about how they have come to understand what happened and how they have changed because of the event.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Psychology Neuroscience + Healthy Habits Disclosure
Description: This condition is a 15 to 20-minute exercise that patients complete in which they examine variables in themselves that suggest that their pain is driven by central nervous system processes in their brains. Followed by writing for 20 minutes a letter to a person of their choosing describing healthy behaviors, a 10 minute break and then a second 20 minute writing task describing a time when they performed a healthy behavior.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Behavior Control + Written Emotional Disclosure
Description: This 15 to 20-minute exercise that relates to healthy behaviors. Participants are asked to examine various domains of their own health behavior as engaged in over the past 24 hours (e.g., nutrition, sleep, exercise, hygiene, social connections). Participants will then write for 20 minutes about their very deepest thoughts and feelings about the most traumatic experience of their lives. A 10-minute break followed by writing again for 20 minutes about how they have come to understand what happened and how they have changed because of the event.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Behavior Control + Healthy Habits Disclosure
Description: This 15 to 20-minute exercise that relates to healthy behaviors. Participants are asked to examine various domains of their own health behavior as engaged in over the past 24 hours (e.g., nutrition, sleep, exercise, hygiene, social connections). Followed by writing for 20 minutes a letter to a person of their choosing describing healthy behaviors, a 10 minute break and then a second 20 minute writing task describing a time when they performed a healthy behavior.
Study: NCT05396248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Retraining Exercises
Description: Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Memory Exercises
Description: Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
Study: NCT05468112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SKY Meditation and Mindfulness
Description: The intervention is a 3-day in-person meditation and mindfulness workshop using the SKY meditation approach. It utilizes a unique set of standardized breathing techniques to rapidly reduce neuro-endocrine stress responses and the autonomic imbalance due to sympathetic overdrive, thus restoring autonomic homeostasis. These are interwoven with coping and stressor appraisal strategies, and simple stretching exercises. Classes will be 3 hours long on each of three consecutive days, and participants must be willing to attend all three sessions with an additional 7 consecutive days of online sessions immediately thereafter. In addition, participants will be asked to engage in daily 10 to 25 minute home resilience practice sessions performed five days per week. They will complete a follow-up session once per week in the subsequent 8 weeks.
Study: NCT05245669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ENZ215
Description: healthy volunteers receive ENZ215 (60mg) once

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU Sourced Prolia
Description: healthy volunteers receive Denosumab (60mg) once

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US Sourced Prolia
Description: healthy volunteers receive Denosumab (60mg) once